SARS-CoV-2 seroprevalence in HIV+ individuals in Germany

SARS-CoV-2 seroprevalence in HIV+ individuals in Germany - ITHF-1-epi

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028631

Enrollment

1300

Registered

2022-03-30

Start date

2020-07-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B24

Interventions

Group 1: Study participants with chronic HIV-Infection: Collection of a single serum sample

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Chronic HIV infection

Exclusion criteria

Exclusion criteria: Vaccination against SARS-CoV-2

Design outcomes

Primary

Measure	Time frame
anti-SARS-CoV-2 spike IgM and IgG levels determined by ELISA	—

Secondary

Measure	Time frame
Statistical analysis of possible relationships between the measured antibody responses against SARS-CoV-2 and 1. Basic patient information 2. Clinical parameters 3. Antiretroviral treatments 4. Socioeconomic factors	—

Countries

Germany

Contacts

Public ContactStefan Esser

Universitätsklinikum Essen, Klinik für Dermatologie

stefan.esser@uk-essen.de+49 201/723-3878

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026